2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1413

Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 52-Week Randomized Controlled Trial and Open-Label Extension Study
Abstract Number: 280

Long-Term Safety and Efficacy Of Etanercept In Paediatric Subjects With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Or Psoriatic Arthritis
Abstract Number: 2142

Long-Term Safety and Efficacy Of Subcutaneous Tanezumab In Patients With Knee Or Hip Osteoarthritis (NCT00994890)
Abstract Number: 310

Long-Term Safety and Tolerability Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis: Pooled Safety Analysis Of Three Phase 3, Randomized, Controlled Trials
Abstract Number: 2342

Long-Term Safety Of Rituximab: Pooled Analysis Of The Rheumatoid Arthritis Global Clinical Trial Program Over 11 Years
Abstract Number: 324

Long-Term Safety Of Ustekinumab: 5 Years Of Follow-Up From The Psoriasis Clinical Development Program Including Patients With Psoriatic Arthritis
Abstract Number: 2345

Long-Term Targeted Safety Event Rates In RA Patients Following Initiation Of Rituximab: Interim Analysis From Sunstone Registry
Abstract Number: 2583

Long-Term Treatment With Endothelin Receptor Antagonist Increases Peripheral Blood Perfusion In Systemic Sclerosis Patients
Abstract Number: 1685

Long-Term Use Of Tocilizumab For The Treatment Of Giant Cell Arteritis
Abstract Number: 1573

Longer Duration Of B Cell Depletion In Patients With Systemic Lupus Erythematosus Is Associated With a Better Outcome
Abstract Number: 1008

Longitudinal Analysis Of Direct Medical Costs For Systemic Sclerosis Patients: A Population-Based Study
Abstract Number: 697

Longitudinal Assessment Of Pulmonary Function In 304 Norwegian Patients With Systemic Sclerosis
Abstract Number: 2604

Longitudinal Assessment Of Scleroderma Skin By Optical Coherence Tomography: Preliminary Validation Of Sensitivity To Change Over-Time
Abstract Number: 1073

Longitudinal Decline In Steps/Day In Older Adults With Or At High Risk Of Knee OA
Abstract Number: 1271

Longitudinal Disease Trajectory Of Juvenile Dermatomyositis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].